DK3984528T3 - Farmaceutiske sammensætninger, som omfatter nilotinib - Google Patents

Farmaceutiske sammensætninger, som omfatter nilotinib Download PDF

Info

Publication number
DK3984528T3
DK3984528T3 DK21194622.3T DK21194622T DK3984528T3 DK 3984528 T3 DK3984528 T3 DK 3984528T3 DK 21194622 T DK21194622 T DK 21194622T DK 3984528 T3 DK3984528 T3 DK 3984528T3
Authority
DK
Denmark
Prior art keywords
nilotinib
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
DK21194622.3T
Other languages
English (en)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3984528(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3984528T3 publication Critical patent/DK3984528T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK21194622.3T 2006-09-27 2007-09-25 Farmaceutiske sammensætninger, som omfatter nilotinib DK3984528T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt
EP15184282.0A EP3009128B1 (en) 2006-09-27 2007-09-25 Pharmaceutical compositions comprising nilotinib

Publications (1)

Publication Number Publication Date
DK3984528T3 true DK3984528T3 (da) 2023-07-31

Family

ID=37684496

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21194622.3T DK3984528T3 (da) 2006-09-27 2007-09-25 Farmaceutiske sammensætninger, som omfatter nilotinib
DK07820560.6T DK2068839T3 (da) 2006-09-27 2007-09-25 Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07820560.6T DK2068839T3 (da) 2006-09-27 2007-09-25 Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf

Country Status (34)

Country Link
US (2) US8293756B2 (da)
EP (4) EP1923053A1 (da)
JP (2) JP5567340B2 (da)
KR (2) KR20090076931A (da)
CN (2) CN104306350A (da)
AR (1) AR062980A1 (da)
AU (1) AU2007301977B2 (da)
BR (1) BRPI0719438B1 (da)
CA (1) CA2662571C (da)
CL (1) CL2007002766A1 (da)
CO (1) CO6160288A2 (da)
CY (2) CY1117021T1 (da)
DK (2) DK3984528T3 (da)
ES (3) ES2957912T3 (da)
FI (2) FI2068839T4 (da)
HR (2) HRP20151383T4 (da)
HU (2) HUE063083T2 (da)
IL (1) IL197496A (da)
JO (1) JO3757B1 (da)
LT (1) LT3984528T (da)
MA (1) MA30807B1 (da)
MX (1) MX2009003184A (da)
MY (1) MY148237A (da)
NO (2) NO347404B1 (da)
NZ (1) NZ575317A (da)
PE (2) PE20081379A1 (da)
PL (2) PL2068839T5 (da)
PT (2) PT2068839E (da)
RU (1) RU2469707C2 (da)
SI (2) SI3984528T1 (da)
TN (1) TN2009000093A1 (da)
TW (3) TW201418245A (da)
WO (1) WO2008037716A2 (da)
ZA (1) ZA200901511B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US8933037B2 (en) 2009-09-28 2015-01-13 Medizinische Universitat Wien Methods involving PDGFRBETA inhibitors
JP5948246B2 (ja) 2009-10-23 2016-07-06 ノバルティス アーゲー Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2011CH01887A (da) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
RU2014120792A (ru) 2011-10-28 2015-12-10 Новартис Аг Способ лечения стромальных опухолей желудочно-кишечного тракта
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
SG11201401476TA (en) * 2011-11-14 2014-10-30 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
IN2014DN10801A (da) 2012-07-11 2015-09-04 Novartis Ag
EP2988729A1 (en) 2013-04-25 2016-03-02 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EP3189045B1 (en) * 2014-08-11 2022-02-09 Sun Pharmaceutical Industries Limited Novel salts of nilotinib and polymorphs thereof
US10045987B2 (en) * 2014-08-28 2018-08-14 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3429589B1 (en) * 2016-03-17 2022-12-14 Sun Pharmaceutical Industries Ltd Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
CN115154437A (zh) * 2021-04-01 2022-10-11 齐鲁制药有限公司 一种含有盐酸尼洛替尼的药物组合物及其制备方法
MX2023015480A (es) 2021-06-19 2024-01-19 Helm Ag Composicion granulada que comprende nilotinib.
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
EP4642435A1 (en) 2022-12-29 2025-11-05 Renata Pharmaceuticals (Ireland) Limited Pharmaceutical suspension of nilotinib
WO2024194718A1 (en) * 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof
CN116854638A (zh) * 2023-06-05 2023-10-10 南华大学 一种含烷基链的氨基酸甲酯类化合物及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DE122007000079I2 (de) 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
PT1200090E (pt) 1999-08-03 2013-11-25 Icos Corp Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CN1674877A (zh) * 2002-06-07 2005-09-28 兰贝克赛实验室有限公司 控释的多单位药物释放系统
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ES2379075T3 (es) * 2002-11-26 2012-04-20 Universiteit Gent Proceso y aparato para granulación húmeda continua de material en polvo
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
EP1776102A1 (en) 2004-07-28 2007-04-25 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
WO2006038552A1 (ja) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. 微粒子含有組成物およびその製造方法
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
ATE525073T1 (de) * 2005-01-28 2011-10-15 Novartis Ag Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
EP1863491A1 (en) * 2005-02-25 2007-12-12 Novartis AG Pharmaceutical combination of bcr-abl and raf inhibitors
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
JP5546860B2 (ja) * 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Also Published As

Publication number Publication date
TWI540128B (zh) 2016-07-01
BRPI0719438B1 (pt) 2022-04-19
CN104306350A (zh) 2015-01-28
HUE063083T2 (hu) 2023-12-28
SI2068839T2 (sl) 2023-01-31
AU2007301977A1 (en) 2008-04-03
TW201418245A (zh) 2014-05-16
CY1126116T1 (el) 2023-11-15
HRP20151383T1 (hr) 2016-01-15
PL2068839T3 (pl) 2016-06-30
ES2957912T3 (es) 2024-01-29
LT3984528T (lt) 2023-08-10
WO2008037716A3 (en) 2008-07-17
CA2662571A1 (en) 2008-04-03
EP3984528A1 (en) 2022-04-20
EP2068839A2 (en) 2009-06-17
CL2007002766A1 (es) 2008-08-08
SI2068839T1 (sl) 2016-02-29
US20130023549A1 (en) 2013-01-24
TWI428333B (zh) 2014-03-01
HUE028204T2 (en) 2016-12-28
KR20090076931A (ko) 2009-07-13
RU2469707C2 (ru) 2012-12-20
EP3984528B1 (en) 2023-07-05
NO20220946A1 (no) 2009-04-24
HRP20151383T4 (hr) 2023-03-03
HK1133193A1 (en) 2010-03-19
CY1117021T1 (el) 2017-04-05
BRPI0719438A2 (pt) 2013-12-10
NO347404B1 (no) 2023-10-16
RU2009115782A (ru) 2010-11-10
US20100087463A1 (en) 2010-04-08
DK2068839T3 (da) 2016-01-11
IL197496A0 (en) 2009-12-24
AU2007301977B2 (en) 2011-09-08
MX2009003184A (es) 2009-04-03
CO6160288A2 (es) 2010-05-20
TW200821298A (en) 2008-05-16
CA2662571C (en) 2016-09-27
FI2068839T4 (fi) 2023-01-31
US8293756B2 (en) 2012-10-23
JP2010504942A (ja) 2010-02-18
ZA200901511B (en) 2010-02-24
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
EP1923053A1 (en) 2008-05-21
IL197496A (en) 2016-04-21
JP5567340B2 (ja) 2014-08-06
JO3757B1 (ar) 2021-01-31
ES2556625T3 (es) 2016-01-19
EP2068839B2 (en) 2022-10-12
FI3984528T3 (fi) 2023-07-27
EP3009128A1 (en) 2016-04-20
PT3984528T (pt) 2023-08-07
PT2068839E (pt) 2015-12-30
KR101598747B1 (ko) 2016-03-02
JP2014065715A (ja) 2014-04-17
NZ575317A (en) 2011-12-22
ES2951547T3 (es) 2023-10-23
PL2068839T5 (pl) 2023-01-30
MY148237A (en) 2013-03-29
HRP20230753T3 (hr) 2023-10-27
CN101516344A (zh) 2009-08-26
TN2009000093A1 (en) 2010-08-19
NO346639B1 (no) 2022-11-07
KR20140121903A (ko) 2014-10-16
AR062980A1 (es) 2008-12-17
PE20081379A1 (es) 2008-11-27
PE20120626A1 (es) 2012-06-07
EP3009128B1 (en) 2023-07-05
MA30807B1 (fr) 2009-10-01
SI3984528T1 (sl) 2023-09-29
NO20091501L (no) 2009-04-24
PL3984528T3 (pl) 2023-08-28
ES2556625T5 (es) 2023-03-02
US8501760B2 (en) 2013-08-06
EP2068839B1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
LTPA2018005I1 (lt) Farmacinė kompozicija
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0719393A2 (pt) Composição farmacêutica
DK2079456T3 (da) Farmaceutiske cyclosporinsammensætninger
DK2068822T3 (da) Selvpræserverede vandige farmaceutiske sammensætninger
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK2041139T3 (da) Farmaceutiske forbindelser
RU2493831C3 (ru) Фармацевтические композиции
DK2399579T3 (da) Farmaceutiske doseringsformer
BRPI0812354A2 (pt) Composição farmacêutica não-aquosa.
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK2120884T3 (da) Farmaceutisk sammensætning
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
BRPI0820198A2 (pt) composições farmacêuticas
DK2001445T3 (da) Farmaceutiske sfæroider
BRPI0811431A2 (pt) Composição farmacêutica aquosa.
DK2252575T3 (da) 2-amino-2-phenylalkanolderivater, fremstilling deraf og farmaceutiske sammensætninger, som indeholder disse
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS